Healthcare - Biotechnology - NASDAQ - US
$ 1.87
-5.08 %
$ 132 M
Market Cap
-0.8
P/E
CASH FLOW STATEMENT
-167 M
OPERATING CASH FLOW
101 M
INVESTING CASH FLOW
53.3 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ventyx Biosciences, Inc.
| Net Income | -193 M |
| Depreciation & Amortization | 941 K |
| Capital Expenditures | -514 K |
| Stock-Based Compensation | 28.6 M |
| Change in Working Capital | 5.81 M |
| Others | -2.34 M |
| Free Cash Flow | -167 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (193.0) | (108.4) | (83.7) | (28.2) | (4.3) |
| Depreciation & Amortization | 0.9 | 0.5 | 30 K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 28.6 | 16.6 | 2.7 | 45 K | 0.2 |
| Other Operating Activities | (8.9) | (2.2) | 38.3 | 21.1 | 0.9 |
| Change in Working Capital | 5.8 | (5.2) | 4.0 | 0.8 | 0.6 |
| Cash From Operations | (166.5) | (98.8) | (38.6) | (6.2) | (2.6) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.5) | (0.3) | (0.3) | 0 | 0 |
| Other Items | 101.5 | (74.7) | (214.1) | 0 | 0 |
| Cash From Investing Activities | 100.9 | (74.9) | (214.4) | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0.5 | 6.1 | 3.0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.9 | 2.4 | 164.3 | 2 K | 1 K |
| Cash From Financing Activities | 53.3 | 167.8 | 323.6 | 6.1 | 3.0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (12.3) | (6.0) | 70.5 | 65 K | 0.3 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (167.0) | (99.0) | (38.9) | (6.2) | (2.6) |